EU regulator okays COVID-19 treatments from GSK-Vir and Sobi
reuters.com ยท
2021-12-16 08:23
Dec 16 (Reuters) - The European Union's drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK GSK and Vir Biotechnology VIR and another from Swedish drugmaker Sobi BIOVF, as the bloc builds its defences against Omicron.
Omicron set to be Europe's dominant variant by early 2022 - ECDCnL1N2T01DJ
COVID SCIENCE-Omicron thrives in airways, not lungs; new data on asymptomatic casesnL1N2T02CQ
FACTBOX-Front runners in development of antibody drugs against COVID-19nL8N2R81NW
FACTBOX-What COVID-19 vaccine and drug makers have to say about OmicronnL4N2SN31Z
(Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru; Editing by Edmund Blair)